

FORM PTO-1449/A and B (modified PTO/SB/08)

APPLICATION NO.: 10/719,493

ATTY. DOCKET NO.: C1039.70021US01

FILING DATE: November 21, 2003

CONFIRMATION NO.: 3218

APPLICANT: Krieg et al.

GROUP ART UNIT: 1643

EXAMINER: Anne Gussow

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AMG/

**U.S. PATENT DOCUMENTS**

Examiner's Initials <sup>#</sup>	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		4,824,775		Dattagupta et al.	04-25-1989
		7,488,490	B2	Davis et al.	02-10-2009
		2004-0052815	A1	Lycke et al.	03-18-2004
		2009-0017021	A1	Davis et al.	01-15-2009
		2009-0060927	A1	Wagner et al.	03-05-2009

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials <sup>#</sup>	Cite No.	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code		
		WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999
		WO	00/06588	A1	University of Iowa Research Foundation	02-10-2000
		WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000
		WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000
		WO	2004/007743	A2	Coley Pharmaceutical GMBH	01-22-2004
		WO	2004/026888	A2	Coley Pharmaceutical GMBH	04-01-2004
		WO	2004/094671	A2	Coley Pharmaceutical GMBH	11-04-2004
		WO	2008/030455	A2	Coley Pharmaceutical Group, Inc.	03-13-2008
		WO	2008/033432	A2	Coley Pharmaceutical Group, Inc.	03-20-2008
		WO	2008/039538	A2	Coley Pharmaceutical Group, Inc.	04-03-2008
		WO	2008/068638	A2	Coley Pharmaceutical GMBH	06-12-2008
		WO	2008/139262	A2	Coley Pharmaceutical GMBH	11-20-2008

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials <sup>#</sup>	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		BODEY et al., Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 2000 Jul-Aug;20(4):2665-76. Review.	
		BOUSSIOTIS et al., B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med. 1993 Nov 1;178(5):1753-63.	
		BRANDA et al., B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol. 1996 May;79(2):115-21.	
		CHATTERJEE et al., Idiotypic antibody immunotherapy of cancer. Cancer Immunol Immunother. 1994 Feb;38(2):75-82. Review.	

EXAMINER:

/Anne M. Gussow/

DATE CONSIDERED:

11/18/2009

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/719,493		ATTY. DOCKET NO.: C1039.70021US01	
				FILING DATE: November 21, 2003		CONFIRMATION NO.: 3218	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1643		EXAMINER: Anne Gussow	
Sheet	2	of	3				

		GOODCHILD et al., Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. <i>Bioconjug Chem.</i> 1990 May-Jun;1(3):165-87.	
		HEEG et al., CpG DNA as a Th1 trigger. <i>Int Arch Allergy Immunol.</i> 2000 Feb;121(2):87-97.	
		KIM et al., TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphomas (CTCL) with CPG7909. <i>Blood.</i> 2004 Nov16;104(11):Abstract #743.	
		KRIEG, Antiinfective applications of toll-like receptor 9 agonists. <i>Proc Am Thorac Soc.</i> 2007 Jul;4(3):289-94.	
		KRIEG, Development of TLR9 agonists for cancer therapy. <i>J Clin Invest.</i> 2007 May;117(5):1184-94.	
		KRIEG, Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. <i>Oncogene.</i> 2008 Jan 7;27(2):161-7. Review.	
		LAGRANDERIE et al., Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. <i>Vaccine.</i> 1993 Oct;11(13):1283-90. Abstract only.	
		LEGENDRE et al., Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. <i>Pharm Res.</i> 1992 Oct;9(10):1235-42.	
		LI et al., Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. <i>Vaccine.</i> 2003 Jul 4;21(23):3319-29.	
		LI et al., Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. <i>J Immunol.</i> 2007 Aug 15;179(4):2493-500.	
		READETT et al., PF-3512676 (CPG7909) a Toll-like receptor 9 agonist – status of development for non-small cell lung cancer (NSCLC). Abstract PD3-1-6. Pfizer. 24 Aug. 2007. Poster.	
		TOKUNAGA et al., Antitumor activity of deoxyribonucleic acid fraction from <i>Mycobacterium bovis</i> BCG. 1. Isolation, physicochemical characterization, and antitumor activity. <i>J Natl Cancer Inst.</i> 1984 Apr;72(4):955-62.	
		VICARI et al., Development of targeted toll-like receptor agonists for cancer therapy. <i>PPO Focus.</i> 2007; 1(2):1-15.	
		VICARI et al., Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. <i>Cancer Immunol Immunother.</i> 2009 Apr;58(4):615-28. Epub 2008 Sep 19.	
		Patent Interference No. 105,526. Krieg Miscellaneous Motion 5 (To exclude exhibits 2066, 2070, 2071, 2072, 2073, 2074, 2075, 2076 and 2078) October 9, 2007.	
		Patent Interference No. 105,526. Raz Opposition 5 (Opposing Krieg Miscellaneous Motion 5) October 25, 2007.	
		Patent Interference No. 105,526. Raz Miscellaneous Motion 7 (To exclude evidence) October 19, 2007.	
		Patent Interference No. 105,526. Krieg Opposition 7 (To Raz Miscellaneous Motion 7) October 25, 2007.	
		Patent Interference No. 105,526. Krieg Reply 5 (Reply to Raz opposition 5) October 30, 2007.	
		Patent Interference No. 105,526. Raz Reply 7 (Reply to Krieg opposition 7) October 30, 2007.	
		Patent Interference No. 105,526. Order – Bd.R. 104. Conference Call. Paper 211. September 30, 2008.	
		Patent Interference No. 105,526. Memorandum Opinion and Order (Decision on Motions) December 1, 2008.	

EXAMINER:	DATE CONSIDERED:
/Anne M. Gussow/	11/18/2009

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/719,493		ATTY. DOCKET NO.: C1039.70021US01		
				FILING DATE: November 21, 2003		CONFIRMATION NO.: 3218		
				APPLICANT: Krieg et al.				
				GROUP ART UNIT: 1643		EXAMINER: Anne Gussow		
Sheet	3	of	3					

		Patent Interference No. 105,526. Judgment on Preliminary Motions under 37 C.F.R. §41.127 December 1, 2008.	
		Patent Interference No. 105,674. Declaration under 37 C.F.R. §41.203(b) December 1, 2008.	
		Patent Interference No. 105,674. Krieg Designation of Real Party in Interest. December 15, 2008.	
		Patent Interference No. 105,674. Paper 19. Order-Bd.R. 104(c). Conference Call. January 16, 2009.	
		Patent Interference No. 105,674. Raz Observations (regarding evidence to support certain proposed motions. January 27, 2009.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:  /Anne M. Gussow/	DATE CONSIDERED:  11/18/2009
-----------------------------------	------------------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.